Scleroderma Research Foundation’s Post

#NASCI2024 has come to a close, showcasing the remarkable advancements in cardiovascular imaging and providing valuable insights into the field of cardiovascular disease. Real-world evidence and real-world imaging data are crucial for comprehending the effectiveness of treatments and patient outcomes in the cardiovascular domain. Segmed provides high-quality, regulatory-grade real-world imaging datasets (RWiD) and multimodal longitudinal datasets that are specifically designed to aid in biomarker discovery and patient identification for treatment in cardiovascular therapy. Connect with us at https://hubs.li/Q02Rh99M0 to learn how our data can support your research and development efforts in the cardiovascular space. #CardiovascularImaging #RWE #RWiD #CardiovascularDisease #PharmaceuticalResearch #MedicalImaging #HealthcareInnovation #ClinicalTrials

The Marga and Walter Boll Foundation supports the development of a groundbreaking platform for research into autosomal dominant polycystic kidney disease (ADPKD) at the University Hospital of Cologne. Over the past eight years, one of the world’s largest ADPKD patient cohorts has been established, providing valuable data for improving treatment and patient counseling. The 'meda' platform was created to make this data more accessible to doctors, scientists, and patients. ADPKD affects an estimated 80,000 people in Germany, often leading to kidney failure, dialysis, or transplantation. With early diagnosis and treatment, the course of the disease can be monitored. The 'meda' platform converts clinical data into a dynamic, web-based system, allowing users to customize analyses and access up-to-date information. This innovative approach improves understanding and participation among stakeholders. The platform is expected to be available to the public by early 2025. “Thanks to funding from the Boll Foundation, my team has succeeded in using the platform to generate the basis for a completely new solution for analyzing and presenting important clinical research data.” Professor Dr. Roman-Ulrich Müller, CECAD Cologne Research Group Leader, University Hospital Cologne   Find out more (in German language only): https://lnkd.in/e9vfxMaD   #BOLLFILTER

What if you could get additional reimbursements vs a Fibroscan for less cost than a Fibroscan? Still sending them out because the ROI doesn’t make sense? How about 10 patients monthly B/E? Let’s talk, I have a better way for you.

Learn more about how blood-based biomarkers (BBMs) can help confirm an Alzheimer’s disease (AD) diagnosis. Dung Trinh, MD, Chief Medical Officer at the Healthy Brain Clinic, gives an overview of BBMs and what this testing method may hold for the future of AD diagnosis in this collaborative video series with Biogen. U.S. HCPs, learn more: https://ow.ly/5FaE50T9KXe #AlzheimersDisease #earlyAD #EndALZ

Serac Healthcare and the University of Exeter have scanned the first patient using technetium-99m maraciclatide, a novel molecular SPECT imaging agent, as part of the phase II PREDICT-ILD study. The research is evaluating quantitative CT for detecting interstitial lung disease progression and a substudy is looking at the prognostic value of Tc-99m maraciclatide

Thomas Bartel, 𝗠𝗗, 𝗣𝗵𝗗, 𝗜𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗮𝗿𝗱𝗶𝗼𝗹𝗼𝗴𝗶𝘀𝘁, 𝗙𝗹𝗲𝘅𝗱𝗼𝗰 𝗚𝗺𝗯𝗛 delves into the multifaceted realm of cardiovascular diagnostics, emphasizing the importance of personalized approaches. From clinical assessments to advanced imaging, this comprehensive exploration underscores how tailoring diagnostics can lead to better patient outcomes. 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: ▪ Clinical Assessment: Anamnesis and vitals remain foundational in personalized care. ▪ Laboratory Diagnostics: Biomarkers and routine screenings are pivotal for early detection and risk profiling. ▪ Instrument-based Diagnostics: Combining functional and morphological diagnostics enhances precision. ▪ Invasive Approaches: Coronary angiography and electrophysiological studies provide critical insights with immediate therapeutic benefits. ▪ Individualization vs. Standardization: Personalizing diagnostic pathways is crucial to cater to unique patient needs and conditions. Embrace a patient-centric approach for better health outcomes. 🔗 https://lnkd.in/ga9R8QmE #Cardiology #Healthcare #PatientCare #Diagnostics #MedicalInnovation #PersonalizedMedicine #HeartHealth #CardiovascularCare #PatientFirst #MedicalAdvancements #HeartDiagnostics #HealthcareInnovation #americanhhm #AmHHM

We are thrilled to announce our partnership with Hall of Fame Health, a collaboration that is integral to our mission at #CereMarkPharma. Together, we aim to enhance outcomes for athletes and soldiers suffering from neurodegenerative diseases. Our joint efforts will drive forward Phase 3 clinical studies of our innovative diagnostic radiopharmaceutical, F-18 Flornaptitril. F-18 Flornaptitril is a cutting-edge PET imaging agent designed to target and visualize the critical pathological proteins associated with Alzheimer's Disease and Chronic Traumatic Encephalopathy (CTE). Our upcoming clinical studies, scheduled to commence later this year, will focus on patients showing initial symptoms of Mild Cognitive Impairment (MCI). This collaboration with Hall of Fame Health is a pivotal step in our mission to provide precise, actionable insights into cognitive health. By combining our expertise in radiopharmaceuticals with Hall of Fame Health's commitment to supporting the healthcare needs of athletes and veterans, we are set to make significant contributions to understanding and managing neurodegenerative diseases. The ability to detect and track the progression of Alzheimer's Disease and CTE in living patients could revolutionize patient management and treatment strategies. You can read more about our partnership in today's Meditech Today: https://lnkd.in/guzr5c_W Stay tuned for more updates on our progress and the potential impact of this collaboration in combating neurodegenerative diseases. We believe this partnership and our forthcoming clinical trials hold the promise of significantly improving outcomes for those affected by these debilitating conditions. #BrainHealth #ClinicalTrials #CTE #AlzheimersDisease #NuclearMedicine #radiopharmaceutical

What is cT1 and why is it important in identifying MASH?   Rajarshi Banerjee: cT1 is Perspectum's proprietary MRI biomarker for the assessment of steatotic liver disease. Through multiple peer reviewed journal articles, cT1 was identified as a key biomarker for risk-stratifying patients with high-risk #MASH. Thanks to its development, patients and physicians now have a noninvasive and accurate means to identify and track #MASH.

Want to explore the future of heart failure treatment without the need for biopsies? Join me on Excellence Talks. InvivoSciences and its co-founder/CEO Ayla's dedication to advancing healthcare through innovation and improving patients' lives worldwide is truly inspiring. Join me as we delve into her insights and experiences, exploring InvivoSciences' mission and the quest for precision medicine on Excellence Talks. Here are some questions we have discussed: 🔹 Why did Ayla co-found InvivoSciences, and what drives the company's mission? 🔹 What key milestones has she achieved in developing precision medicines for genetically defined heart failures, and what challenges has she encountered? 🔹 What is needed to achieve the pending milestones of InvivoSciences' drug program, and how does Ayla plan to address these needs? 🔹 How does precision cardiology approach HFpEF cardiac disease differently from current methodologies, and how does InvivoSciences bridge this gap? Don't miss this opportunity to learn from a leader in the field. Watch the video below to gain valuable insights into the future of heart failure treatment. #PrecisionMedicine #HealthcareInnovation #Cardiology #InvivoSciences #excellencetalks #technology@heartfailureforpreservedejection

Exciting News: CE Mark for Siemens Healthineers NfL Assay! 🎉 Thrilled to share that our Neurofilament Light Chain (NfL) assay for the Atellica IM Analyzer and ADVIA Centaur XP/XPT Systems, developed with #Novartis, has achieved the CE Mark.* This innovative blood test can help predict MS disease activity in patients with Relapsing Multiple Sclerosis (RMS), potentially preventing relapses and improving patient care. NfL also shows promise in supporting the diagnosis and management of other neurological diseases. We look forward to pioneering more healthcare breakthroughs. Learn more: https://lnkd.in/euGmA_sv #MultipleSclerosis #Diagnostics #Innovation #Collaboration #siemenshealthineers *This product is not yet commercially available in all countries. Not for sale in the USA. Future availability cannot be guaranteed.